当前位置:科学网首页 > 小柯机器人 >详情
整合素α4β7抗体无法用于治疗猴免疫缺陷病毒
作者:小柯机器人 发布时间:2019/9/6 12:36:45

美国国立卫生研究院Mario Roederer研究组的一项最新研究发现,阻碍整合素α4β7与猴免疫缺陷病毒的结合并不能提高病毒控制效果。2019年9月6日,《科学》发表了这项成果。

一项针对非人类灵长类动物的研究报告说,与抗逆转录病毒疗法相结合,输入针对α4β7整合素的抗体,显示出对恒河猴中猿猴免疫缺陷病毒(SIV)的一致、持久的控制。

那项研究中所使用的抗体具有多效性,因此研究人员通过比较这种治疗方法与针对SIV包膜糖蛋白的非中和性单克隆抗体的治疗进行比较来深入了解其潜在机制,该抗体仅阻断α4β7与SIV衣壳的结合,而没有其他宿主效果。与最初的研究相似,研究人员使用了在nef基因上含有终止密码子的SIV减毒株。这项研究使用了30只猕猴,这些猕猴都在开始时接受了抗逆转录病毒治疗,然后分成五组接受不同的抗体治疗。与已发表的报告不同,研究人员发现这些治疗在体内没有持续的病毒控制效果。

附:英文原文

Title: Blocking α4β7 integrin binding to SIV does not improve virologic control

Author: Nami Iwamoto, Rosemarie D. Mason, Kaimei Song, Jason Gorman, Hugh C. Welles, James Arthos, Claudia Cicala, Susie Min, Hannah A. D. King, Aaron J. Belli, Keith A. Reimann, Kathryn E. Foulds, Peter D. Kwong, Jeffrey D. Lifson, Brandon F. Keele, Mario Roederer

Issue&Volume: Volume 365 Issue 6457

Abstract: A study in nonhuman primates reported that infusions of an antibody against α4β7 integrin, in combination with antiretroviral therapy, showed consistent, durable control of simian immunodeficiency virus (SIV) in rhesus macaques. The antibody used has pleiotropic effects, so we set out to gain insight into the underlying mechanism by comparing this treatment to treatment with non-neutralizing monoclonal antibodies against the SIV envelope glycoprotein that only block α4β7 binding to SIV Env but have no other host-directed effects. Similar to the initial study, we used an attenuated strain of SIV containing a stop codon in nef. The study used 30 macaques that all began antiretroviral therapy and then were divided into five groups to receive different antibody treatments. Unlike the published report, we found no sustained virologic control by these treatments in vivo.

DOI: 10.1126/science.aaw7765

Source:https://science.sciencemag.org/content/365/6457/1033

期刊信息
Science:《科学》,创刊于1880年。隶属于美国科学促进会,最新IF:41.037